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Abstract
Objective: Women diagnosed with breast cancer younger than 45 years (young 
breast cancer survivors—YBCS) and their biological relatives face significant stress-
ors. Although family support is an important coping resource, little is known about 
YBCS’ and relatives’ support and whether it is interdependent. The study described 
family support in YBCS and their biological relatives; identified demographic, clini-
cal, and psychosocial predictors of support; and determined the interdependence of 
support in YBCS- relatives family units.
Methods: Data were collected from a random sample of YBCS and their first- or 
second- degree female relatives. Actor- partner interdependence models (APIM) ex-
plored predictors and interdependence of YBCS’ and relatives’ family support in 
dyads (YBCS and relative) and triads (YBCS and two relatives).
Results: Among n = 310 YBCS and n = 431 first- or second- degree relatives, family 
support was higher in triads compared to dyads. APIMs identified actor effects in 
dyads, and actor and partner effects in triads. Across all family units, YBCS’ higher 
self- efficacy was associated with higher YBCS support (actor effect) and relative 
support (partner effect); YBCS’ prior diagnosis of depression was associated with 
lower YBCS and relative support (actor and partner effect); cost- related lack of ac-
cess to care was associated with lower support among YBCS (actor effect) and rela-
tives (actor and partner effect).
Conclusions: Family support was interdependent and was affected by self- efficacy, 
depression, and access to care. Interventions should include YBCS and relatives, 
enhance self- efficacy and access to care.
K E Y W O R D S
Actor-Partner Interdependence Model, dyads, principal component analysis, random sample, triads, 
young breast cancer survivors
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1 |  BACKGROUND
Breast cancer is the most prevalent female cancer world-
wide, with 1.38 million new cases annually.1 About 25% 
of all breast cancer cases are diagnosed in women under 
50 years old, constituting a growing clinical population 
of younger women with breast cancer.2 Early onset breast 
cancer presents several challenges, including tumors that 
are more aggressive, higher recurrence rates, and increased 
mortality, and is associated with genetic predisposition. 
First- and second- degree relatives of young breast cancer 
survivors (YBCS) have a 2.3 and 1.5 increased relative risk 
for breast cancer, respectively.3
YBCS often report poorer outcomes compared to their 
older counterparts due to different stressors and social 
roles.4,5 YBCS caring for young children may face additional 
difficulties communicating concerns and may feel respon-
sible for transmitting an increased cancer risk to their off-
spring.4,5 Caring for children and older parents, combined 
with the challenges of the disease, can cause additional dis-
tress, anxiety, depression, fear of recurrence, and difficulties 
returning to work.4,6,7 Loss of income due to inability to work 
can lead to additional financial stressors and lack of access to 
care.5 Thus, YBCS may need significantly more support to 
overcome these challenges compared to older breast cancer 
patients.8
Although biological female relatives have an elevated 
risk for breast cancer, they may not always cope with this 
risk and manage it effectively. Young women with a strong 
family history may have heightened perceptions of breast 
cancer risk, chronic depression, anxiety, and increased 
breast cancer worry.9-11 Family members are an import-
ant source of information about risk factors, genetics, and 
available screening and risk- reducing strategies, especially 
for women from medically underserved communities.12 
Multiple family members are likely to be involved, directly 
or indirectly, in appraisals regarding the magnitude of 
the health threat and the availability of coping resources. 
However, family members may perceive different levels of 
vulnerability and stigmatization associated with hereditary 
breast cancer, experience different levels of distress, and 
disagree about the extent of family involvement needed 
to reduce these stressors.13-15 Input from different family 
members affects support they are willing to give and re-
ceive to each other.
There is a need to promote long- term coping in YBCS 
and relatives and to mitigate the burden of early onset breast 
cancer.4,5 Family support is essential to successful coping 
of breast cancer patients16 and can decrease cancer- related 
distress.17 Individuals involved in reciprocal relationships 
usually influence each other’s thoughts, emotions, and 
coping behaviors.18 Yet, little is known about a possible 
interdependence of family support in YBCS and biological 
relatives, who also face an increased breast cancer risk due 
to heredity. The study addressed this gap in the literature. 
Specific aims were to describe family support in YBCS 
and their relatives; identify demographic, clinical, and psy-
chosocial characteristics as predictors of family support; 
and determine the interdependence of support in YBCS- 
relatives family units.
1.1 | Theoretical framework
The study was guided by the integration of the theory of 
stress and coping19 with the theory of family systems in 
genetic illness20 applied to families with hereditary breast 
cancer risk.21 Stress occurs when primary appraisals of a 
health problem threaten one’s well- being.19 Primary ap-
praisals include YBCS’ and relatives’ assessment of stress-
ors associated with early onset breast cancer, for example, 
cost of health care. Primary appraisals may interfere with 
the ability to withstand stress because they can exacerbate 
YBCS’ depression and fear of cancer recurrence, and in-
crease relatives’ perceived breast cancer risk.22,23 Initial 
appraisals are followed by appraisals about the avail-
ability of personal (eg, self- efficacy for managing breast 
cancer23) and social coping resources (eg, family support) 
that can help manage the health threat. Family support is 
the  primary outcome of the study in both YBCS and their 
 relatives (Figure 1).
F I G U R E  1  Theoretical framework
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2 |  METHODS
2.1 | Design, setting, and sample
The study used baseline data obtained with a self- 
administered survey for an efficacy trial designed to increase 
surveillance and use of cancer genetic services in YBCS 
and their first- and second- degree relatives (ClinicalTrial.
gov ID:NCT01612338).24 All Institutional Review Boards 
involved in the identification, recruitment, and consent of 
participants approved the study protocol. Methodological 
and recruitment details have been reported.24,25 A random 
sample of 3000 YBCS was selected from the Michigan 
Cancer Surveillance Program (MCSP). Age criteria for 
YBCS vary among studies from 40 to 50 years old and 
under; we were conservative in our sample selection and 
we chose a cutoff of 45 years or younger at the time of di-
agnosis. The sample was stratified by race (1500 Black vs 
1500 White/Other YBCS) to ensure an adequate representa-
tion of Black YBCS. The “Other” category includes about 
7% of Michigan YBCS not recorded in the registry as Black 
or White (eg, Arab American). Due to their small numbers, 
YBCS of other racial/ethnic backgrounds could not form a 
separate stratum. YBCS were eligible to participate if they 
were diagnosed with invasive breast cancer or ductal car-
cinoma in situ (DCIS); were younger than 45 years old at 
the time of diagnosis and younger than 65 years old at the 
time of the study; and were willing to invite one or two rela-
tives in the study. Relatives had to be female and in first- or 
second- degree biological relationship with the YBCS. They 
had to be younger than 65 years old and cancer- free at the 
time of the study.
Prior to contacting the YBCS, the director of the MCSP 
inquired with the reporting facility and physician of record 
whether there was any reason that the YBCS could not 
participate in the study. If MCSP did not receive a nega-
tive response within 30 days, an invitation letter explaining 
the study, a consent form, a self- administered baseline sur-
vey, and a stamped return envelope were mailed to YBCS. 
Eligible YBCS received up to three mailed invitations to 
participate in the study. In order to have family units with 
comparable size, the study invited up to two relatives per 
YBCS. There were 58 YBCS carrying a mutation associ-
ated with hereditary breast cancer who were excluded from 
this paper; their relatives were not invited in the efficacy 
trial since the focus was to increase use of genetic services 
among untested families.
2.2 | Instruments
The study outcome was family support in YBCS and rela-
tives. According to the theoretical framework, predictors 
included stressors for YBCS (lack of access to care due to 
cost, anxiety, depression, and fear of cancer recurrence) and 
for relatives (perceived breast cancer risk), resources for 
YBCS (self- efficacy dealing with breast cancer), and demo-
graphic characteristics for both YBCS and relatives.
2.2.1 | Family support
Family support was conceptualized as open communication, 
support in times of illness, and coherence, and was meas-
ured with three well- established scales. All items were rated 
on a seven- point Likert scale, ranging from one “Strongly 
Disagree” to seven “Strongly Agree.” Family communica-
tion was assessed with the Lewis Mutuality and Interpersonal 
Sensitivity Scale (MIS),26 validated with breast cancer survi-
vors and their family members.27,28 MIS includes 15 items 
(eg, “The people in my family change the topic when I dis-
cuss my concerns”); internal consistency in this study was 
0.94. Family support in times of illness was assessed with 
the Family Support in Illness scale, originally developed for 
women pursuing breast cancer screening.29 The scale in-
cludes 10 items (eg, “In our family, when I have a health 
problem, there is someone helping me get the care that I 
need”); internal consistency in this study was 0.91. Family 
coherence is the ability of the family to cope with adverse 
events and was assessed with the Family Hardiness Index 
(FHI),30 validated with cancer and noncancer patients.31,32 
FHI includes 20 items (eg, “In our family we have a sense 
of being strong even when we face big problems”); internal 
consistency was 0.90.
A family support index was created from these three 
scales. Principal component analysis (PCA) examined the 
correlations of items (n = 45). The Kaiser- Meyer- Olkin mea-
sure of sampling adequacy and Bartlett’s test of sphericity 
indicated that PCA was possible. PCA identified a primary 
component of family support. Pearson correlation coeffi-
cients in the component matrices ranged between 0.40 and 
0.80. Four items did not correlate adequately with the princi-
pal component and were not used. An overall family support 
index was created by calculating a mean score from the three 
scales as the dependent variable.
2.2.2 | Stressors
Cost-Related Lack of Access to Care was assessed with one 
item asking YBCS and relatives “Has there been a time within 
the past 12 months that you needed to see a doctor or have a 
medical test but you could not because of high out- of- pocket 
cost?” yes/no; yes indicates cost- related lack of access to care.
Anxiety and Depression were assessed with two items asking 
YBCS and relatives “Have you ever been told by a healthcare 
provider that you have anxiety?” yes/no and “Have you ever 
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been told by a health care provider that you have depression?” 
yes/no. These variables were assessed because they interfere 
with support and communication,33,34 and better family func-
tioning mitigates depressive symptoms among cancer patients.35
Fear of Cancer Recurrence (YBCS only) was assessed 
with four items from the Concerns About Recurrence Scale 
(CARS) (eg, “How much time do you spend thinking about 
your breast cancer coming back”) using a seven- point Likert 
scale from one “Not at all” to seven “All the time”.36 Internal 
consistency was 0.91.
Perceived Breast Cancer Risk was assessed with one item 
asking YBCS and relatives to rate their chances of (another) 
getting breast cancer on a 10- point Likert scale with verbal 
anchors “Definitely will not” to “Definitely will”.37
2.2.3 | Resources
Self- efficacy managing breast cancer (YBCS only) was as-
sessed with 14 items (eg, “Since my breast cancer diagnosis, 
I am able to do the things that are important for me”) scored 
on a seven- point Likert scale, ranging from one “Strongly 
Disagree” to seven “Strongly Agree”.38 Internal consistency 
was 0.95.
Demographic and Clinical Characteristics such as age, 
education, income, living alone, relative being first vs. sec-
ond degree, years since diagnosis, number of cancer diagno-
ses were assessed in YBCS and relatives with items from the 
Behavioral Risk Factors Surveillance System Survey39 and 
items developed by the team.40
F I G U R E  2  Results of actor- partner 
interdependence models (APIM) of family 
support
APIM of family support in YBCS and their biological relatives 
YBCS: Young Breast Cancer Survivor; R: Relative
Solid lines: actor effects
Dashed lines: partner effects 
FSYBCS: Family Support in YBCS; FSR: Family Support in Relative
AYBCS = YBCS actor effects; AR = Relative actor effects
PYBCS-R = YBCS partner effects YBCS to Relative; PR-YBCS = partner effects Relative to YBCS
Note: Statistically significant (P < 0.05) unstandardized coefficients for paths are displayed, followed by standard
errors in parentheses; *P < 0.05, **P < 0.01, ***P < 0.001. Baseline covariances and AR1 AR2 paths are not 
included in figures for simplicity as they are equivalent to AR1 AR1 and AR2 AR2 paths. 
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2.3 | Statistical analyses
Analyses were performed with SPSS® version 22.041 and 
MPlus version 7.0.42 Sample characteristics, stressors, and 
resources were described with means, standard deviations 
(SD), frequencies (n), or percentages (%), depending on 
scaling and data distribution. A P value ˂0.05 was consid-
ered statistically significant in all analyses. Demographics 
and clinical characteristics were included in all models as 
covariates.
Data from dyads and triads often violate the fundamental 
assumption of many data analyses methods that data are col-
lected from independent subjects. YBCS and relatives have 
an existing interpersonal relationship; thus, correlations be-
tween YBCS’ and relatives’ data need to be taken into ac-
count. The Actor- Partner Interdependence Model (APIM) has 
been used to study complex dynamics in families and close 
relationships.43 It assesses interdependence and bidirectional 
effects within interpersonal relationships.44 Observation in-
terdependence necessitates examining the dyad (ie, the pair) 
as a single unit of analyses, rather than two units (ie, as single 
individuals). Interdependence means that observations from 
two or more individuals are linked. Knowledge of one’s char-
acteristics (actor) can provide information about the other 
person’s (partner) attitudes, etc. Assessing bidirectionality 
involves examining each person’s influence on the other per-
son’s outcomes.
We identified three types of family units for this study: 
dyads consisting of one YBCS and one relative; triads con-
sisting of one YBCS and two relatives; and YBCS with no 
eligible relatives or whose relatives did not accept partici-
pation. The latter group was excluded from APIM analyses 
and this paper. APIM examined predictors of family support 
in dyads and triads. A dyadic model captured the interde-
pendence of family support between YBCS and one relative 
(Figure 2A), and a triadic model among YBCS and two rela-
tives (Figure 2B). Actor effects are observed when character-
istics of one person (eg, their own resources) are significant 
predictors of their own outcome (ie, family support), regard-
less of whether this is an YBCS or a relative. Partner effects 
refer to cross- dyadic or cross- triadic associations and are ob-
served when characteristics of one person in the family influ-
ence family support reported by another member.
We examined evidence of nonindependence in the out-
come variable (family support index) by assessing the level of 
intraclass correlations.18,43 Intraclass correlations in dyads and 
triads were statistically significant (0.31, 95% CI 0.17- 0.43, 
ANOVA F = 1.88, P < 0.001; and 0.37, 95% CI 0.23- 0.50, 
ANOVA F = 2.16, P < 0.001, respectively), suggesting inter-
dependence of support in family units and that analyses should 
follow a dyadic and triadic format. Data were restructured in 
dyads including one YBCS and one relative and triads includ-
ing one YBCS and two relatives. Mixed predictor variables 
(variables that exhibit both between- and within- dyad/triad 
variability) were used to estimate the interdependence effects 
of family support.18,43,44 Full information on maximum likeli-
hood estimation (FIML) was used in path analyses. FIML pro-
duces unbiased estimates based on all available information 
from variables included in an analysis, when data are missing 
at random or missing completely at random.
A fundamental tenet of dyadic analyses is determining 
distinguishability, meaning, whether or not there is a way 
to treat each individual as different.18 Distinguishable dyads 
are, for example, heterosexual couples; indistinguishable 
dyads are, for example, same- sex roommates. We could dis-
tinguish members of dyads (YBCS and relatives), but we 
were unable to distinguish the two female relatives included 
in triads. The two relatives in triads were treated as indistin-
guishable, because there were no specific criteria that could 
designate one relative as a primary participant and the other 
relative as a secondary participant. Consequently, we used a 
novel approach for triadic analyses based on analyses meth-
ods of indistinguishable dyads. In indistinguishable dyads, 
data from the two individuals are pooled in order to produce 
parameter estimates.18,45,46 Following this approach, in the 
triadic APIM we pooled the estimates from the two relatives 
into one estimate by imposing equality constraints. Pooling 
the estimates from two indistinguishable relatives allowed 
us to estimate the effects from the two relatives as a single 
“relative” effect.
Indicators of adequate model fit in triadic APIM were 
a comparative fit index (CFI) above 0.90, a nonsignificant 
chi- square statistic or a ratio of chi- square statistic to degrees 
of freedom (df) less than two, a root mean squared error of 
approximation (RMSEA) value of 0.08 or less, and a stan-
dardized root mean square residual (SRMR) value of 0.08 or 
less.47,48 We tested both an unconstrained dyadic model (fully 
saturated) and a constrained dyadic model (with actor = actor 
and partner = partner) constraints.49 A significant difference 
between the unconstrained and constrained model suggests 
that the actor effects and partner effects were equal for YBCS 
and relatives.
3 |  RESULTS
3.1 | Sample characteristics
From the 3000 identified YBCS, n = 883 accepted participa-
tion (response rate 33.2% after excluding deceased, missing 
current address etc.). From these 883 YBCS, n = 573 par-
ticipated in the study alone, either because they had no eli-
gible relatives or because their relatives did not accept study 
participation.25 To address APIM analyses, in this paper we 
include only those YBCS, n = 310, who participated in the 
study with one or two relatives.
   | 4985KATAPODI eT Al.
The 310 YBCS and their 431 blood female relatives 
constituted 189 dyads (one YBCS and one relative) and 
121 triads (one YBCS and two relatives). Most family units 
(n = 249) included only first- degree relatives (n = 164 
dyads; n = 85 triads); 32 family units included only second- 
degree relatives (n = 25 dyads; n = 7 triads); 29 triads were 
mixed, with both first- and second- degree relatives. YBCS 
were on average 51 years old at the time of the study and 
11 years postdiagnosis; approximately one in five (19.7%) 
had more than one cancer diagnoses. Most YBCS were 
White/Other, had an annual household income less than 
$80 000, had some college- level education or above, and 
were married. Relatives were on average 43 years old; most 
were White/Other, had an annual household income less 
than $60 000, had some college- level education or above, 
and were married (Table 1).
Participants reported high levels of family support on 
the three family support scales (ie, communication, sup-
port in illness, and coherence) (observed range: 5.4- 6.1) 
and the family support index (YBCS: 5.6 ± 0.9; relatives: 
5.7 ± 0.9) (Table 2). Relatives reported significantly 
higher family communication compared to YBCS. White/
Other participants (YBCS and relatives combined) re-
ported a higher score on the Family Support in Illness scale 
compared to Black participants (6.0 ± 1.1 vs. 5.8 ± 1.2, 
P = 0.001); this difference was not observed in the other 
two scales. Family support in illness was also higher in tri-
ads than dyads (Table 3).
3.2 | Predictors of family support in 
dyads and triads—APIM
3.2.1 | Dyadic findings
APIM with 189 dyads (YBCS and one relative) identi-
fied significant actor effects in YBCS and relatives, but no 
partner effects (Table 4). First, we tested an unconstrained 
dyadic model, which allowed actor and partner effects to 
differ between YBCS and relatives and found significant 
actor effects. As this dyadic model was a saturated model 
without fit indices, we tested an additional model where 
we constrained the actor effects to be equal to each other 
and the partner effects also to be equal to each other. No 
constraints were placed on dyad- level predictors, that is, 
years since diagnosis, race, and degree type; on variables 
measured only in YBCS, that is, fear of recurrence and 
self- efficacy. Chi- square difference tests revealed that the 
effects did not differ across YBCS and relatives in the dy-
adic model (Χ2diff = 15.390, df = 18, P = 0.6350). Thus, 
we report the constrained model results in Table 4. Similar 
to the unconstrained model, only actor effects were sig-
nificant; a prior diagnosis of depression and cost- related 
lack of access to care were associated with lower family 
support for YBCS and relatives. The strength of the actor 
effects between depression and cost- related lack of access 
to care did not differ between YBCS and relatives. More 
years since diagnosis and higher self- efficacy were associ-
ated with higher family support for YBCS, whereas Black 
race was associated with higher family support in relatives.
3.2.2 | Triadic findings
With the exception of the CFI (0.616), model fit indices were 
acceptable in the APIM triad analyses (nonsignificant chi- 
square, P = 0.0552; X2/df ratio = 1.18; RMSEA = 0.038; 
SRMR = 0.057). APIM with 121 triads (YBCS and two 
relatives) identified significant actor and partner effects 
(Table 4). YBCS’ self- efficacy was associated with higher 
YBCS family support. YBCS having cost-related problems 
to accessing care and more years since diagnosis were associ-
ated with lower YBCS family support. Black race in relatives 
was associated with higher relative family support, while rel-
atives’ cost- related lack of access to care was associated with 
relatives’ lower family support. Four partner effects were 
identified in triads. YBCS’ prior diagnosis of depression was 
associated with relatives’ lower family support; YBCS’ older 
age and higher self- efficacy were associated with relatives’ 
higher support; and relatives’ higher income was associated 
with YBCS’ higher support.
4 |  DISCUSSION
Early onset breast cancer can have a profound impact on 
cancer patients and their families. YBCS are a special group 
who have to manage both their own disease and their family 
roles. Their biological relatives also have to realize, accept, 
and manage a higher breast cancer risk. Family support is a 
valuable resource that can help address these challenges.
4.1 | Family support in YBCS and relatives
Relatives reported higher family communication compared 
to YBCS, possibly due to YBCS’ unmet communication 
needs, especially for illness- related issues.50,51 White/Other 
participants (YBCS and relatives combined) reported higher 
family support at times of illness compared to Black partici-
pants. This could be partly because Black YBCS were sig-
nificantly more likely to invite relatives living further than 50 
miles away to participate in the study with them (data shown 
elsewhere),25 which could affect tangible support offered and 
received at times of illness. Triads reported higher family 
support at times of illness compared to dyads, presumably 
because it can be more difficult to find support from others at 
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T A B L E  1  Sample characteristics
YBCS (n = 310) Relatives (n = 431) P value
Demographics
Age (mean ± SDa) 51.4 ± 5.8 43.4 ± 11.9 <0.001
Race (N, %b)
White/other 242 (78.1%) 344 (79.8%)
Black 68 (21.9%) 87 (20.2%) 0.629
Education (N, %b)
Elementary school only 0 (0%) 2 (0.5%)
High school (grades 9- 11) 2 (0.7%) 9 (2.1%)
Compulsory education 
(K- 12)
56 (18.3%) 61 (14.4%)
Some college 113 (36.9%) 157 (37.0%)
Completed college 74 (24.2%) 126 (29.7%)
Postgraduate degree 61 (19.9%) 69 (16.3%) 0.109
Employment (N, %b)
Full time 157 (50.7%) 237 (57%)
Part time 42 (13.5%) 64 (15.4%)
Unemployed/otherc 111 (35.8%) 115 (27.6%) 0.357
Income (N, %b)
<$20 000 24 (8.7%) 51 (13.2%)
$20 000- $39 999 42 (15.2%) 84 (21.8%)
$40 000- $59 999 50 (18.1%) 68 (17.6%)
$60 000- $79 999 51 (18.4%) 53 (13.7%)
$80 000- $99 999 30 (10.8%) 36 (9.3%)
$100 000- $119 999 29 (10.4%) 33 (8.5%)
>$120 000 51 (18.4%) 61 (15.8%) 0.103
Marital status (N, %b)
Married/life partner 212 (68.4%) 257 (59.8%)
Single/divorced/widowed 98 (31.6%) 173 (40.2%) 0.020
Lives alone 44 (14.2%) 60 (13.9%) 0.998
Clinical characteristics
Years since 1st diagnosis 
(mean ± SDa)
11.6 ± 4.0 N/Ad
Anxiety (N, %b) 89 (29.1%) 115 (27.1%) 0.604
Depression (N, %b) 84 (27.5%) 111 (26.1%) 0.731
Stressors
Cost- related lack of access 
to care (N, %b)
56 (18.1%) 82 (19.2%) 0.779
Fear of cancer recurrence 
(mean ± SDa)
3.4 ± 1.6 N/Ad
Perceived breast cancer risk 
(mean ± SDa)
N/Ad 4.7 ± 2.0
Resources
Self- efficacy (mean ± SDa) 5.9 ± 1.1 N/Ad
aStandard deviation. 
bValid percentages. 
cStudent, retired, housewife. 
dN/A: not applicable. 
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that time. Participating in the study with two vs one relative 
may indicate a stronger and larger support network.
4.2 | Predictors and interdependence of 
family support
APIM examined both actor and partner effects, with the for-
mer being primary predictors of family support. Partner ef-
fects were observed only in triads, possibly due to greater 
chances of one person affecting the other person’s responses.
4.2.1 | Self- efficacy
Consistent with other studies, YBCS’ breast cancer self- 
efficacy was an important predictor of their own family sup-
port (actor effect).52,53 In dyads and triads, YBCS with more 
confidence in their ability to manage demands associated with 
breast cancer reported higher family support. Self- efficacy is 
a key resource for cancer survivors associated with important 
outcomes, such as better mental health54 and higher quality 
of life.55 A novel finding of our study was that YBCS’ higher 
self- efficacy had a significant partner effect on relatives’ per-
ceived family support in triads. Relatives may find it easier to 
help YBCS who have higher self- efficacy and fewer needs, 
as it may be less burdensome. YBCS who are better able 
to manage disease- related stressors by themselves may feel 
more self- reliant, creating less strains and demands on their 
family. YBCS with lower self- efficacy is a group at risk for 
adverse outcomes and warrants further assessment and early 
intervention. In contrast, YBCS with higher self- efficacy 
could be a resource for their relatives, who may also ben-
efit from support in managing their own anxiety about cancer 
risk. This reciprocal relationship merits more investigation.
4.2.2 | Cost and access to care
About one in five YBCS and one in five relatives reported 
that there was a time during the past 12 months that they 
needed medical care but could not get it due to high out- of- 
pocket costs. Higher income is usually associated with avail-
ability of expendable resources to address illness- related 
expenses.7,56 Cancer may cause significant financial burdens 
and high out- of- pocket costs for YBCS; lack of support and 
available resources at times of need may further deter YBCS 
from accessing care. Relatives with higher income had a 
positive partner effect on YBCS’ family support in triads, 
possibly because they are considered an actual or potential 
resource to YBCS, accounting for YBCS perceiving higher 
support from them.
4.2.3 | Depression
YBCS with a prior diagnosis of depression reported lower 
family support (actor effect). Depression during diagnosis 
and treatment worsens for some breast cancer patients, espe-
cially for those lacking a partner or other forms of support.57,58 
Relatives who reported lower family support were also more 
likely to report a prior diagnosis of depression (actor effect in 
dyadic relationships) or to be associated with an YBCS with 
depression (partner effect in triadic relationships). The part-
ner effects of YBCS’ prior diagnosis of depression indicate 
that YBCS’ depressive symptoms may influence relatives’ 
perceived family support. Relatives are expected to provide 
support to cancer survivors, although they also experience 
stressors and need support59; when relatives are depressed, 
they may perceive receiving less support, possibly as appre-
ciation for their efforts.60 In a prior APIM analyses with a 
different sample of cancer survivors and their family caregiv-
ers, we also identified significant longitudinal partner effects 
between cancer patients’ depression and their family car-
egivers.61 Helping YBCS and relatives identify and manage 
depression is an important intervention area. However, we 
T A B L E  2  Family support in YBCS and relatives
YBCS (N = 310) 
mean ± SDa
Relatives 
(N = 431) 
mean ± SDa P value
Family 
communication
5.4 ± 1.1 5.6 ± 1.1 0.040
Family support 
in illness
6.0 ± 1.1 6.1 ± 1.0 0.087
Family 
coherence
5.4 ± 0.8 5.5 ± 0.8 0.688
Family Support 
Index
5.6 ± 0.9 5.7 ± 0.9 0.112
aStandard deviation. 
Dyads (n = 189) 
mean ± SDa
Triads (n = 121) 
mean ± SDa P value
Family communication 5.4 ± 1.2 5.6 ± 1.0 0.437
Family support in illness 6.0 ± 1.1 6.2 ± 1.0 0.038
Family coherence 5.4 ± 0.8 5.5 ± 0.7 0.287
Family Support Index 5.6 ± 0.9 5.7 ± 0.8 0.134
aStandard deviation. 
T A B L E  3  Mean family support in 
family units
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acknowledge that our findings may be influenced by partici-
pants’ recall bias, since we measured anxiety and depression 
with single- item questions asking participants to recall what 
was told to them.
4.2.4 | Race
The activation of family support, which often increases with 
the burden of illness, can strengthen family relationships but 
T A B L E  4  Actor- partner interdependence models^
Actor effects
Dyads Triads
Estimate P value Estimate P value
YBCS
First- degree relationship* −0.166 0.364 0.191 0.226
Age 0.001 0.788 0.011 0.502
Black race* 0.285 0.068 0.014 0.949
Education 0.082 0.053 −0.073 0.329
Income −0.010 0.308 0.008 0.573
Single relationship status −0.159 0.175 −0.082 0.724
Lives alone −0.103 0.491 0.101 0.714
Years since diagnosis* 0.040 0.015 −0.050 0.031
Anxiety −0.198 0.075 −0.212 0.250
Depression −0.282 0.014 −0.308 0.098
Cost- related lack of access to care −0.302 0.007 −0.395 0.046
Fear of recurrence* 0.048 0.286 0.025 0.649
Self- efficacy* 0.288 <0.001 0.303 <0.001
Perceived risk −0.004 0.857 −0.004 0.911
Relatives
First- degree relationship* 0.098 0.572 0.219 0.092
Age 0.001 0.788 0.001 0.697
Black race* 0.419 0.005 0.424 0.022
Education 0.082 0.053 0.057 0.171
Income −0.010 0.308 0.002 0.807
Single relationship status −0.159 0.175 −0.087 0.340
Lives alone −0.103 0.491 0.113 0.408
Years since diagnosis* −0.002 0.883 −0.023 0.224
Anxiety −0.198 0.075 0.119 0.265
Depression −0.282 0.014 −0.025 0.819
Cost- related lack of access to care −0.302 0.007 −0.225 0.016
Perceived risk 0.004 0.857 −0.026 0.198
Partner effects†
YBCS → relative
Age 0.007 0.202 0.032 0.017
Depression −0.168 0.148 −0.369 0.017
Self- efficacy* 0.067 0.309 0.116 0.047
Relative → YBCS
Income 0.010 0.298 0.019 0.034
Unstandardized estimates (B) and standard errors (SE) reported.
^The dependent variable of the APIM analyses is the Family Support Index (PCA of the three scales); boldface indicates P < 0.05.
†Only significant (P < 0.05) partner effects in the triad data are reported along with the complementary nonsignificant results in the dyadic analysis; no significant 
(P < 0.05) partner effects were observed in dyadic data. 
*Dyad- level predictors were degree type, race, and years since diagnosis; fear of recurrence and self- efficacy were reported only by YBCS. 
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can also strain network ties. In the face of a cancer diagno-
sis, family resources may be more readily available for some 
YBCS, or conversely not available for others, bringing up 
any differences in perceived family support that may have 
existed prediagnosis. Relatives of Black YBCS may hold 
strong beliefs about their familial obligations, due to strong 
familial and community orientations.62 Expressions of fa-
milialism and collectivism are more evident in Blacks than 
other racial groups, due to a traditional caregiving ideology, 
related to collectivism in social relationships.63 However, 
this finding should be interpreted with caution, since there 
were a smaller number of Black relatives in the study and the 
other group included White YBCS and a small proportion of 
YBCS of other ethnic/racial background.
4.2.5 | Length of survivorship
Finally, being a longer- term cancer survivor was associated 
with less family support reported by YBCS in triadic rela-
tionships. Since YBCS in the study were diagnosed on aver-
age 11 years prior, family members may assume that YBCS 
need less support over time. This may not necessarily be ac-
curate, as some YBCS may have to cope with late effects of 
cancer treatment or pervasive fear of cancer recurrence.64,65 
YBCS’ age had a positive partner effect on relatives’ family 
support, presumably because some longer- term cancer survi-
vors focus less on their own needs and more on the needs of 
their families.66
4.3 | Strengths and limitations
Limitations include self- reporting and recruitment prefer-
ences. Relatives were invited directly from YBCS, which as-
sumes that relatives in good relationship with the YBCS were 
prioritized; this may explain the small range of scores in the 
family support index (5.3- 6.1; possible range 1- 7). The study 
invited up to two relatives per YBCS for comparable family 
units, although some YBCS may be receiving support from 
larger networks. Stressors, that is anxiety and depression, 
were assessed with single- item measures instead of length-
ier instruments to reduce overall burden, but responses may 
be influenced by recall bias. YBCS of “other” racial/ethnic 
backgrounds were combined with White YBCS, thus find-
ings related to race may not be generalized. Finally, we did 
not assess whether YBCS were receiving treatment, which 
may have implications for family support they needed at the 
time of the survey.
Future research with YBCS and relative triads may con-
sider a conceptually meaningful way to distinguish relatives 
as part of the study design and in line with the study aims. For 
example, the study could have required YBCS to designate 
one relative who provides more support. However, prior work 
of the research team demonstrated that cancer patients have 
difficulty and may feel uncomfortable about making a choice 
and indicating who provides more support. Thus, we consider 
that extending the term “family” to include more than two 
people and attending to the challenges associated with these 
complex analyses are significant strengths of our study.
We examined self- efficacy as a predictor of family sup-
port, which is not the way it has been traditionally examined 
in prior literature. Our findings indicate a strong correlation 
between family support and patients’ self- efficacy (ie, pa-
tients’ confidence in their own ability to manage the dis-
ease). Traditionally, family support has been examined as a 
predictor of self- efficacy. An alternative hypothesis suggests 
that the ability of people to provide support is associated 
with the characteristics of the person needing support. It 
may be more difficult to support cancer patients who have 
low self- efficacy (ie, low self- confidence) in their ability to 
manage the disease. It is possible that the support person 
may need to spend more time bolstering or encouraging the 
patient with low self- efficacy, which may become burden-
some over time. Further research is needed in this area. Due 
to the cross- sectional nature of the data, we can only report 
the significant correlation between self- efficacy and support 
rather than confirm causation from one variable to the other 
variable.
4.4 | Implications
Family support enhances the long- term physical and 
mental well- being of cancer patients and their family 
members.6,16,67-69 It also provides greater cohesion and 
strengthens the interpersonal contacts among breast can-
cer patients and their relatives.67 Our findings demonstrate 
the interdependence of family support between YBCS and 
their close biological relatives. APIM provided valuable 
insights into complex family relationships taking also into 
account relatives’ increased breast cancer risk due to possi-
ble hereditary susceptibility. Consistent with our theoretical 
framework, self- efficacy and access to care were important 
resources that influence family support. Perceived stress-
ors associated with early onset breast cancer and avail-
ability of resources may affect the level of support family 
members are willing to give and receive to each other. Due 
to the interdependence among YBCS and their relatives, 
supportive programs need to focus on the YBCS- relative as 
the unit of care and include family- based interventions that 
enhance each person’s self- efficacy and access to high- 
quality services.70-72 Existing evidence- based interventions 
for cancer patients and their family caregivers72-75 could be 
adapted to address the needs of YBCS and their relatives. It 
is also important for researchers and clinicians to work to-
gether and develop technology- based dyadic interventions 
that are cost- effective and accessible to a large number of 
families.76–78
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